CME on 21st March 2025 on Bone disorders in Kidney patients
AIIMS Nagpur’s Department of Nephrology Hosts Multidisciplinary Clinical Meeting on Mineral Bone Disorder, Osteoporosis, and Fragility Fractures in Chronic Kidney Disease
21st March 2025, AIIMS Nagpur : The Department of Nephrology , AIIMS Nagpur in association with The Nephrology Society Nagpur, successfully organized a Multidisciplinary Clinical Meeting (CME) focusing on Mineral Bone Disorder (CKD-MBD), Osteoporosis, and Fragility Fractures in Chronic Kidney Disease (CKD).
The event was graced by Dr. Prof. Prashant P. Joshi, Executive Director and CEO of AIIMS Nagpur, as the Chief Guest. The guests of honor were Dr. Shivnarayan Acharya, Senior Nephrologist, and Dr. Pramod Gandhi, Senior Endocrinologist.
Expert talks & Panel Discussion
The CME featured experts who provided valuable insights into the evaluation and management of CKD-related bone disorders:
- Sakshi Mittal – Evolving concepts in the Pathophysiology of CKD-MBD
- Kishore Kumar – Diagnostic challenges & advances
- Manoj Dhanorkar – Innovations in treatment
The session concluded with an interactive panel discussion facilitated by Dr. Anand Chellappan, Associate Professor and In-Charge, Department of Nephrology, AIIMS Nagpur. The expert panel included:
- Nephrologists : Dr. Prakash Khetan, Dr. Suryashree Pandey, Dr. Amit Pasari
- Endocrinologist : Dr. Pooja Jadhao
- Orthopedician : Dr. Saurabh Sah
Key Takeaways from the CME
- Patients with CKD have a 3-5x higher risk of osteoporosis and fractures due to altered bone metabolism. Early diagnosis and appropriate intervention is crucial.
- CKD-related bone disease is complex, ranging from Adynamic Bone Disease (Low turnover) to High-Turnover Bone disease (Secondary Hyperparathyroidism). Correct classification guides treatment.
- Bone Mineral Density (BMD) assessment, combined with biochemical markers, aids in early diagnosis and individualized treatment for bone disorders in CKD.
- A Multidisciplinary Team approach could help improve diagnosis and to provide tailored therapies in the field of CKD-associated osteoporosis.
- Emerging therapies, including novel anti-resorptive and anabolic agents, show promise in managing CKD-MBD while balancing calcium-phosphorus metabolism.